GIANTCR Trademark

Trademark Overview


On Monday, April 15, 2024, a trademark application was filed for GIANTCR with the United States Patent and Trademark Office. The USPTO has given the GIANTCR trademark a serial number of 98501127. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, April 15, 2024. This trademark is owned by SCG Cell Therapy Pte Ltd.. The GIANTCR trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Culturing of cells for scientific research purposes; Cell culture services for scientific and research purposes, for others; Scientific research in the nature of conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials; Pharmaceutical research and development; Research and development for the pharmaceutical industry; Research and development in the field of biotechnology; Research and development in the field of diagnostic preparations; Research and development in the field of microorganisms and cells; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Research and development services in the field of immunology; Advisory services relating to scientific research; Biochemical research and development; Biomedical research services; Biotechnology research; Chemical research and analysis; Clinical research in the fields of viral disease, cancer, and cell therap...
giantcr

General Information


Serial Number98501127
Word MarkGIANTCR
Filing DateMonday, April 15, 2024
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateMonday, April 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesCulturing of cells for scientific research purposes; Cell culture services for scientific and research purposes, for others; Scientific research in the nature of conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials; Pharmaceutical research and development; Research and development for the pharmaceutical industry; Research and development in the field of biotechnology; Research and development in the field of diagnostic preparations; Research and development in the field of microorganisms and cells; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Research and development services in the field of immunology; Advisory services relating to scientific research; Biochemical research and development; Biomedical research services; Biotechnology research; Chemical research and analysis; Clinical research in the fields of viral disease, cancer, and cell therapy; Consultancy in the field of pharmaceutical research; Consultancy relating to pharmaceutical research and development; Gene therapy research; Laboratory research services relating to pharmaceuticals; Medical research services; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific research and development; Stem cell research; Advisory services relating to gene therapy research

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, April 15, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSCG Cell Therapy Pte Ltd.
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressSingapore 109683
SG

Trademark Events


Event DateEvent Description
Monday, April 15, 2024NEW APPLICATION ENTERED